Atopic dermatitis (eczema): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• JAK 7
• IL-4 1
• IL-13 2
• STAT3 1
• MAPK 0
• TNF 0
• PDE4 1
• TSLP 0
• NLRP3 0
• PPAR 0
• IL-6 0
• NRF2 0
• GLP-1 0
• AKT 0
• FOXP3 0
• HMGB1 0
• JNK 0
• STING 1
• ERK 0
• HSP90 0
• IL-1 0
• IL-17 0
• mTOR 0
• PI3K 0
• TYK2 0
• YAP 0
• CD19 0
• CTLA-4 0
• CTNNB1 0
• FAK 0
• PD-1 0
• TLR4 0
• AMPK 0
• BCL-2 0
• CD38 0
• COX-2 0
• CXCR4 0
• DPP-4 0
• EGFR 0
• FTO 0
• G6PD 0
• HIF-1 0
• IL-15 0
• IL-23 0
• MEK 0
• PD-L1 0
• PINK1 0
• PTEN 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,596 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Dupilumab De-escalation in Pediatric Atopic Dermatitis

  NCT06116526· Johns Hopkins University· Updated 3 Nov 2026

  “Poor accrual”Registry text, quoted unchanged. Source

• Terminated

  Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT06058156· Sanofi· Updated 3 Nov 2026

  “Sponsor decision. Not related to safety concern.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07330934· Innovent Biologics (Suzhou) Co. Ltd.· Updated 27 Oct 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Educational Eczema Video Intervention

  NCT03664271· Boston Children's Hospital· Updated 19 Oct 2026

  “never obtained funding”Registry text, quoted unchanged. Source

• Terminated

  A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

  NCT05486208· Eli Lilly and Company· Updated 13 Oct 2026

  “Study terminated due to lack of efficacy signal in atopic dermatitis participants.”Registry text, quoted unchanged. Source

• Suspended

  A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

  NCT07265479· Organon and Co· Updated 5 Oct 2026

  “As a precaution, study drug dosing is paused due to a PK finding in OG505-3104. No safety signal or change to the established safety or benefit-risk profile has been identified. The Sponsor is further investigating and assessing the data.”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  Replication of the Heads Up Atopic Dermatitis Trial With Registry Data

  NCT06937788· Technische Universität Dresden· Updated 28 Aug 2026

  “Recruitment targets (sample size) could not be met within the planned time frame.”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase 1 Study of Cizutamig in IgE Mediated Diseases

  NCT07408869· Candid Therapeutics· Updated 22 Jul 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort

  NCT04818138· Women's College Hospital· Updated 21 Jul 2026

  “End of funding period.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

  NCT07527923· Regeneron Pharmaceuticals· Source

• A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

  NCT07783425· Pfizer· Source

• Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation

  NCT07919899· Sanofi· Source

• A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

  NCT06807281· Pfizer· Source

• A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

  NCT07216027· Pfizer· Source

• A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

  NCT06863961· Hoffmann-La Roche· Source

• Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT06058156· Sanofi· Source

• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

  NCT02612454· Regeneron Pharmaceuticals· Source

• A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Janssen Research & Development, LLC· Source

• This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

  NCT07290803· Sanofi· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 17
• Organoids 2
• Mendelian Randomization Analysis 26
• Gene Expression Profiling 43
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 19
• Metabolomics 11
• Mass Spectrometry 1
• Flow Cytometry 7
• Immunohistochemistry 6
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 2
• Machine Learning 20
• Cohort Studies 64
• Genome-Wide Association Study 28

• Artificial intelligence in pediatric allergic diseases: what the clinician needs to know.

  Eur J Pediatr, Nov 2026

• Machine learning-based prediction of food sensitization in infants and toddlers with atopic dermatitis.

  Pediatr Allergy Immunol, Oct 2026

• Identification and experimental validation of CCL26 as a core comorbid gene and biomarker for atopic dermatitis and allergic asthma via machine learning and multi-omics analysis.

  Front Immunol, Sept 2026

• Multimodal protective and susceptibility clusters in paediatric atopic dermatitis: A machine learning-based, data-driven observational study.

  PLoS Med, Sept 2026

• Integrative transcriptomic analysis identifies CCL22-associated immune signatures in air pollution-related atopic dermatitis.

  Front Public Health, Sept 2026

• Exploring and validating hub genes associated with atopic dermatitis through weighted gene co-expression network analysis and machine learning.

  Medicine (Baltimore), Aug 2026

• Integrating network pharmacology, machine learning, and molecular docking to explore the therapeutic mechanisms of Huangqin in atopic dermatitis: A STROBE-compliant observational study.

  Medicine (Baltimore), Jul 2026

• Machine learning reveals distinct temperature thresholds and environmental modulators for atopic dermatitis and allergic contact dermatitis prevalence in South Korea.

  PLoS One, Jul 2026

• Immunological differences in atopic dermatitis across age groups: insights from single-cell multi-omics.

  J Transl Med, Jun 2026

• Identification of Lipid Metabolism-Related Gene GM2A as a Potential Biomarker in Atopic Dermatitis by Combining Weighted Gene Co-Expression Network Analysis and Machine Learning.

  DNA Cell Biol, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.